Example HBS Cohorts.

Longitudinal example data (NSCLC)

NSCLC patients with samples collected across multiple time points and matched metastatic sites — for tracking biomarker evolution and treatment response over the disease course.

Data categories capturedDemographicsHistologyStaging (TNM, grade, AJCC)Primary tumorMatched metastases (up to 5 sites, dates & treatment status)Treatment lines (neoadjuvant, adjuvant, subsequent) with agents & tumor responseRecurrence / progression sitesOutcomes & cause of deathTime-to-event metrics (OS, PFS in months)Event flags

	Donor	Any Immunotherapy	Specimen TreatmentSubgrouping	Specimen Tumour Site	Primary TumourSite	# matched mets
▸	Donor #001	No	Treatment naïve	Lung, left upper lobe	—	1
▸	Donor #002	No	Treatment naïve	Left lung, upper lobe	—	2
▸	Donor #003	No	Treatment naïve	Lung, right upper lobe	—	1
▸	Donor #004	Yes	Treatment naïve	Lung, left upper Lobe	—	2
▸	Donor #005	No	Treatment naïve	Lung, right lower Lobe	—	4
▸	Donor #006	Yes	Treatment naïve	Lung, right lower Lobe	—	2
▸	Donor #007	No	—	—	Left lung upper lobe	3

CRC Molecular & follow up data examples

CRC molecular and follow-up data — KRAS / NRAS / BRAF / MMR / MSI / EGFR pathway and downstream IHC characterization with linked outcomes.

Data categories capturedTumor sidednessMolecular: KRAS / NRAS / BRAF mutationsMMR / MSI status with MLH1, PMS2, MSH2, MSH6 IHCDemographicsStaging (TNM, grade)Primary tumorMatched metastasesMatched normal tissueTreatment lines (neoadjuvant with TRS, adjuvant, subsequent) with agents & tumor responseRecurrence / progression sitesOutcomes & cause of deathTime-to-event metrics (OS, PFS in months)Event flags

Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	Detected (c.436G>A), p.(Ala146Thr)	A146T	Normal	Positive	Positive	Positive	Positive	Not Detected	Not Detected	No	—	Yes	—	Orthopaedic pinning lower limb	—	Sigmoid Colon	A1	Right proximal femur	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Metastatic adenocarcinoma consistent with a colorectal	Primary tumour	Yes	3	2	NR	—	T3N2M0	M	AJCC 5	III	No	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, fluorouracil, folinate (4 cycles)	Lungs (new mets), Liver (new met)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Mixed therapy	Bevacizumab, raltitrexed (8 cycles)	PR	Radiotherapy	8Gy in 1# (rib, vertebra)	NR	Mixed therapy	Bevacizumab, oxaliplatin, raltitrexed (1 cycle)	NR	Chemotherapy	Oxaliplatin, raltitrexed	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	—	35.87	—	—	—	—	—	2.07	4.3	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	13.47	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	26.63	31.67	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	13.47	37.57	36.47	—	37.57	13.47	1	1	1	1	L	NR	NR	Normal	Positive	Positive	Positive	Positive	Not Detected	Not Detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
R	c.437C>T (p.Ala146Val)	A146V	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Right hemicolectomy	Ascending colon	—	A6	Terminal ileum (serosal deposit)	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma (NOS)	Specimen	Yes	4a	1c	1c (peritoneum)	1b (liver, aortocaval node)	T4AN1CM1C	M/W	AJCC 8	IVC	No	—	—	—	—	—	—	—	Chemotherapy	IrOxMdG (8 cycles) Irinorecan, Oxaliplatin, Calcium folinate, Fluororacil	Liver (larger met)	Lungs (new mets), Liver (new met)	Lung (larger mets), Liver (new mets)	Liver (new and larger mets), Lung (new and larger mets)	Liver (larger mets), Lung (larger mets), Lymph nodes (new mets)	Liver (larger mets), Lung (larger mets), Lymph nodes (larger mets)	Liver (new and larger mets), Lung (new and larger mets), Adrenal (new met)	—	—	—	—	—	—	—	—	Chemotherapy	IrOxMdG (8 cycles) Irinorecan, Oxaliplatin, Calcium folinate, Fluororacil	SD	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	PR	Chemotherapy	OxaliCap (3 cycles) Oxaliplatin, Capecitabine	PD	Chemotherapy	IrinoCap (4 cycles) Irinotecan, Capecitabine	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	Metastatic colon cancer	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.53	6.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	10.67	15.57	17.57	22.37	25.73	29.27	34.37	—	—	—	—	—	—	—	—	2.53	6.63	17.4	19.9	23.63	25.97	26.9	29.17	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	10.67	34.87	34.37	—	34.87	10.67	1	1	1	1	R	—	A11	normal	positive	positive	positive	positive	—	—
L	Detected (c.437C>T) / p.(Ala146Val)	A146V	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	—	Total exenteration of pelvis	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	4A	—	NR	—	T4AN0M0	W/M	AJCC	IIB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	LH20-33159	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
L	Detected (c.437C>T, p(Ala146Val).	A146V	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	—	Laparoscopic APER and right inguinal lymphadenectomy	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	No	3	—	1a (R groin lymph nodes)	1 (lung)	T3N0M1B	M	AJCC 8	IVB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	LH21-4646	A1	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
R	Detected G12Xaa	G12	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	—	No	—	Right posterior sectionectomy	—	Caecum	A3	Liver	Treatment naïve	A2	Liver	Q3 - 2019	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Metastatic colorectal adenocarcinoma	Primary tumour	Yes	3	—	NR	1A (Liver)	T3N0M1A	M	AJCC 8	IVA	No	—	—	—	—	—	—	—	—	—	lungs (new mets)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Chemotherapy	Fluorouracil, folinate	NR	Other	Zolendronate	—	Radiotherapy	20Gy in 5# (mandible)	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	1.77	3.37	3.37	—	—	—	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	21.83	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	47.83	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	21.83	59.3	51.93	—	59.3	21.83	1	1	1	1	R	NR	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	c.35G>C (p.Gly12Ala)	G12A	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Sigmoid colectomy	Sigmoid colon	—	A24	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	Yes	3	1b	NR	—	T3N1BM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (3 cycles)	Lung (new mets), Liver (new mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.37	4.27	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.67	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.67	9.73	8.2	—	9.73	7.67	1	1	1	1	L	—	A8	normal	positive	positive	positive	positive	—	—
R	Detected (c.35G>C)/p.(Gly12Ala)	G12A	Normal	Positive	Positive	Positive	Positive	Not detceted	Not detected	No	Treatment naïve	No	—	Right hemicolectomy and anastomosis nec	Caecum	—	A12	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	No	3	1B	X	—	T3N1BM0	W/M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (8 cycles; 3 weeks)	Left lower lung, left hilar lymph node (New mets)	Left Upper and Lower Lung (New mets)	Liver (New mets)	Lung and Liver (New and larger mets)	Nodes (New mets), Lung (New and larger mets)	Lung, Liver (New and larger mets)	—	—	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, Fluorouracil (9 cycles)	PR	Chemotherapy	Irinotecan and Fluorouracil (6 cycles)	SD	Chemotherapy	Trifluridine and Tipiracil (2 cycles)	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Type 2 diabetes mellitus, hypertension	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.6	—	1.6	—	—	—	—	—	3.03	9.53	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	32.8	43.43	48.63	51.27	55.5	62.5	—	—	—	—	—	—	—	—	—	35.6	40.4	45.23	47.9	52.13	54.6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	32.8	70.8	62.5	—	70.8	32.8	1	1	1	1	R	LH17-52059	NR	Normal	Positive	Positive	Positive	Positive	Not detceted	Not detected
L	Detected (c.35G>C)/p.(Gly12Ala)	G12A	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Anterior resection of rectum and anastomosis nec	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	1	—	X	—	T1N0M0	W/M	AJCC 8	I	No	—	—	—	—	—	—	—	—	—	Liver (New met)	Liver (New and larger metss)	Lung (New mets)	Lung (Larger mets)	Lung, nodes (New mets)	Lung (New and larger mets), Nodes (Larger mets)	Lung, nodes (Larger mets)	Brain (New mets), Eye (new met)	Nodes, Lung (Larger mets)	Adrenals (New mets)	Brain (New Mets)	Nodes, adrenal (Larger mets)	Lung, nodes (Larger mets; marginal increase)	Brain (New mets)	—	Chemotherapy	Oxaliplatin, Capecetabine (4 cycles)	PR	Chemotherapy	Irinotecan, 5 Fluorouracil, Calcium folinate (6 cycles)	PR	Radiotherapy	8Gy1#(lung, mediastinal & hilar nodes)	PD	Radiotherapy	24Gy1# (Brain)	PR	Radiotherapy	20Gy5# (R orbit)	PD	Chemotherapy	Irinotecan and Fluorouracil (6 cycles)	MR	Chemotherapy	Oxaliplatin and Cepecitabine (4 cycles)	PD	Radiotherapy	24Gy1# (Brain)	NR	Chemotherapy	Trifluridine and tipiracil (1 cycle)	PD	Deceased	Yes	Metastatic rectal cancer	asthma, hyperthyroidism	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.57	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	19.63	21.2	32.13	37.07	42.4	47.67	54.17	54.43	56.47	59.03	61.5	62.7	64.47	66.47	—	22.93	25.13	46.5	48.9	50.17	50.17	55.13	55.13	55.47	55.6	56.9	59.3	60.2	62.4	62.13	62.13	63.47	63.47	—	—	—	—	—	—	—	—	—	—	—	—	19.63	68.13	66.73	—	68.13	19.63	1	1	1	1	L	LH17-55608	A1	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	Detected c.34G>T p. Gly12Cys	G12C	—	—	—	—	—	Not detected	Not detected	No	—	Yes	—	T11 vertebratectomy and rib resection	—	Rectum	C4	T11 (spine)	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Metastatic rectal adenocarcinoma	Primary tumour	NR	3	1	1 (liver)	1 (Liver)	T3N1M1 (Liver)	M	AJCC	IVA	Yes	NR	Radiotherapy	25Gy in 5# (rectum)	NR	—	—	—	Chemotherapy	Oxaliplatin, capecitabine (7 cycles)	lungs (new mets), pelvis (local recurrence)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Mixed therapy	Irinotecan, fluorouracil, folinate (2 cycles), Irinotecan, fluorouracil, folinate, aflibercept (16 cycles)	SD	Radiotherapy	10Gy in 1# (spinal cord), 8Gy in 1# (rib)	PR	Chemotherapy	Irinotecan, fluorouracil, folinate (28 cycles)	SD	Radiotherapy	8Gy in 1# (spinal nerve root)	NR	Radiotherapy	8Gy in 1# (rib)	NR	Radiotherapy	8Gy in 1# (clavicle)	NR	Other	Denosomab (2 cycles)	NR	Mixed therapy	Irinotecan, fluorouracil, folinate, bevacizumab (6 cycles)	SD	—	—	—	Deceased	Yes	NR	Data Not Collected	Specimen surgery is post subsequent Tx 5	3.23	3.43	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	3.6	60.17	—	—	—	—	—	5.83	10.37	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	16.2	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	17.37	28.2	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	16.2	68.07	67.67	—	68.07	16.2	1	1	1	1	L	13H021516	NR	—	—	—	—	—	Not detected	Not detected
L	Detected c.34G>T p. Gly12Cys	G12C	—	—	—	—	—	Not detected	Not detected	No	—	Yes	—	Left temporal and right occipital craniotomies and debulking of tumours	—	Rectum	B2	Brain, left temporal lobe	Immunotherapy naïve	A2	Brain, right occipital lobe	Q3 - 2019	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Primary tumour	Yes	2	—	NR	—	T2N0M0	M	AJCC 5	I	Yes	NR	Chemotherapy	Capecitabine (1 cycle)	NR	Radiotherapy	45Gy in 25# (rectum)	NR	—	—	Brain (new mets)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Radiotherapy	24Gy in 1# (brain met); 6Gy in 1# (brain met 2)	PR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	—	2	3.17	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	6.93	19.23	19.23	—	—	—	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	32.9	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	9.3	9.5	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	32.9	23.2	34.07	—	23.2	32.9	1	1	1	1	L	LH19-8641	NR	—	—	—	—	—	Not detected	Not detected
L	c.34G>T, p.(Gly12Cys)	G12C	Normal	Positive	Positive	Positive	Positive	—	—	No	Immunotherapy naïve	No	—	Abdominoperineal excision of rectum and end colostomy	Rectum	—	B9	Lymph node	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	3	1C	NR	—	T3N1CM0	W/M	AJCC 8	IIIB	Yes	2	Radiotherapy	25Gy in 5# (Rectum)	SD	—	—	—	—	—	Lung (New mets)	Lung (Larger mets)	Lymph nodes (New mets)	Lung (Larger mets)	liver (New mets), lung (Larger mets), pelvic sidewall (new/larger mets)	Lung, Liver (Larger mets)	Lung (Larger mets). Liver (larger met)	—	—	—	—	—	—	—	—	Chemotherapy	Fluorouracil, Irinotecan (8 cycles)	PR	Mixed treatment	Oxaliplatin, Fluorouracil, Bevacizumab (13 cycles)	SD	Chemotherapy	Fluorouracil, Irinotecan (8 cycles)	SD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	benign prostatic hyperplasia, Hydrocele	—	1.3	1.43	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	4.37	—	4.37	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	16.37	19.4	20.47	30.3	34.1	47.6	47.6	—	—	—	—	—	—	—	—	22.07	25.33	35.97	47.57	48.47	52.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	16.37	—	52.4	52.4	52.4	16.37	1	—	—	1	L	LH20-32724	Bx	Normal	Positive	Positive	Positive	Positive	—	—
R	Detected (c.34G>T) / p.(Gly12Cys)	G12C	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	laparoscopic assisted right hemicolectomy and ileostomy	Caecum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	No	3	—	X	—	T3N0M0	W/M	AJCC 8	IIA	No	—	—	—	—	—	—	—	—	—	Peritoneum (New met)	Peritoneum (New met/residual disease)	Peritoneum (Larger met)	Peritoneum (Larger met)	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, Capecitabine (4 cycles)	PR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	NR	Subsequent breast cancer	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	13	21.83	24.2	26.9	—	—	—	—	—	—	—	—	—	—	—	28.03	30.83	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	13	—	58.27	60.23	60.23	13	1	—	—	1	R	—	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
L	Detected (c.34G>T) / p.(Gly12Cys)	G12C	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	—	Anterior resection of rectum and anastomosis nec	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	3	1B	NR	—	T3N1BM0	W/M	AJCC	IIIB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	—	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
L	Detected c.34G>T p.(Gly12Cys)	G12C	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	—	Yes	—	Left hemihepatectomy	—	Sigmoid Colon	B2	Liver	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Metastatic colorectal cancer	Primary tumour	Yes	3	2	X	—	T3N2M0	M/P	AJCC 5	III	No	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, capecitabine (4 cycles)	Liver (new met), Lung (new met)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Chemotherapy	Irinotecan, capecitabine (5 cycles)	PD	Chemotherapy	Oxaliplatin, capecitabine (4 cycles)	MR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	1.2	25.03	—	—	—	—	—	4.87	7.67	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	11.03	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	39.47	41.9	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	11.03	45.8	45.03	—	45.8	11.03	1	1	1	1	L	LH17-16291	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
R	Detected (c.34G>T), p.(Gly12Cys)	G12C	—	—	—	—	—	Not Detected	Not Detected	No	Treatment naïve	No	—	Right hemicolectomy and anastomosis nec	Right (ascending) colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	3	1	NR	—	T3N1M0	M	AJCC 5	III	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	R	—	NR	—	—	—	—	—	Not Detected	Not Detected
L	Detected. c.34G>T p.(Gly12Cys)	G12C	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	—	Sigmoid colectomy and exteriorisation of bowel NEC	Sigmoid Colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	3	1c	NR	1b (Lung and liver)	T3N1cM1b	M	AJCC 8	IVB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	H2207211	A5	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
R	c.35G>A (p.Gly12Asp)	G12D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Laparoscopic converted to open right hemicolectomy	Ascending colon	—	A16	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	Yes	4a	1b	x	—	T4AN1BM0	M/P	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (4 cycles)	Liver (multiple new mets)	Liver (new and larger mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	OXMdG (6 cycles) Oxaliplatin, Fluorouracil, Calcium folinate	MR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Previous basal cell carcinoma	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.77	—	0.77	—	—	—	—	—	2.77	5.33	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.3	10.57	—	—	—	—	—	—	—	—	—	—	—	—	—	10.07	12.43	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.3	15.4	12.53	—	15.4	7.3	1	1	1	1	R	—	A19	normal	positive	positive	positive	positive	—	—
R	c.35G>A (p.Gly12Asp)	G12D	abnormal	negative	negative	positive	positive	—	—	No	Treatment naïve	No	—	Right hemicolectomy	Caecum	—	A21	Lymph node	Treatment naïve	B1	Abdominal wall	Q1 - 2019	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Mucinous adenocarcinoma	Specimen	No	4b	2b	M0 - direct invasion of ovary/fallopian tube	1a (ovary/fallopian tube)	T4BN2BM0	P	AJCC 8	IIIC	No	—	—	—	—	—	—	—	—	—	Abdomen & pelvis (new mets), Lung (new met)	Abdomen (larger mets), Lung (larger mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	Radiotherapy	30Gy in 10 # (Abdomen)	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Hypertension, asthma, depression	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.43	6.8	—	—	—	—	—	—	—	—	—	—	—	—	—	4.67	5.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.43	8.53	6.8	—	8.53	3.43	1	1	1	1	R	—	A9	abnormal	negative	negative	positive	positive	—	—
R	c.35G>A (p.Gly12Asp)	G12D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Laparotomy approach	Caecum	—	A4	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	LH19-02906	A6	Distal resection margin	Q1 - 2019	Treatment naïve	M	Adenocarcinoma (NOS)	Specimen	Yes	4b	2a	—	1 (?peritoneum)	T4BN2AM0	P	AJCC 8	IIIC	No	—	—	—	—	—	—	—	—	—	Peritoneum (new mets)	Peritoneum (new and larger mets), Liver (new mets)	Peritoneum (larger mets),Liver (new and larger mets)	Peritoneum (larger mets), Liver (new and larger mets), abdominal lymph nodes (new mets)	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	OxaliCap (3 cycles) Oxaliplatin, Capecitabine	PD	Chemotherapy	IrinoCap (2 cycles) Irinotecan, Capecitabine	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	1a) Metastatic caecal adenocarcinoma	Type 2 diabetes, hypertension, gout, previous cholecystectomy	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	25.87	28.4	29.43	31.37	—	—	—	—	—	—	—	—	—	—	—	27.57	29.6	29.9	31.17	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	25.87	32.87	31.37	—	32.87	25.87	1	1	1	1	R	—	A9	normal	positive	positive	positive	positive	—	—
L	c.35G>A (p.Gly12Asp)	G12D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Anterior resection of rectum	Rectum	—	A17	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	LH19-31604	A2	Distal resection margin	Q3 - 2019	Treatment naïve	M	Adenocarcinoma (NOS)	Specimen	Yes	3	1a	NR	—	T3N1AM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	OxaliCap (6 cycles) Oxaliplatin, Capecitabine	Liver (new mets), Lung (new met)	Liver (larger mets), Lung (larger mets)	Liver (larger mets), Lung (new and larger mets)	Liver (larger mets), Lung (larger mets)	Liver (larger mets), Lung (larger mets)	Liver (larger mets), Lung (larger mets)	Liver (progression), Ascites	—	—	—	—	—	—	—	—	Chemotherapy	IrMdG (12 cycles) Irinotecan, Calcium folinate, Fluorouracil	PR	Chemotherapy	IrinoCap (6 cycles) Irinotecan, Capecitabine	PD	Chemotherapy	OxaliCap (3 cycles) Oxaliplatin, Capecitabine	PR	Chemotherapy	TRIFLURIDINE + TIP (3 cycles) Trifluridine with Tipiracil	PD	Chemotherapy	IrinoCap (14 cycles) Irinotecan, Capecitabine	SD	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Hypertension, Sleep apnoea, Type 2 diabetes, obesity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.5	—	2.5	—	—	—	—	2.5	5.53	8.37	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	14.03	24.43	30.53	36.17	38.9	45	49.07	—	—	—	—	—	—	—	—	15.4	21.47	25.47	28.37	31.1	34	36.47	38.93	40.4	50.67	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	14.03	52.63	49.07	—	52.63	14.03	1	1	1	1	L	LH19-19884	NR	normal	positive	positive	positive	positive	—	—
R	c.35G>A (p.Gly12Asp)	G12D	abnormal	negative	negative	positive	positive	—	—	Yes	Treatment naïve	No	—	Laparoscopic total colectomy	Ascending colon	—	A13	Lymph node/satellite tumour deposit	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Mucinous adenocarcinoma	Specimen	Yes	3	2a	NR	1a (liver)	T3N2AM1A	W/M	AJCC 8	IVA	No	—	—	—	—	—	—	—	—	—	Omentum (new mets)	Omentum, peritoneum (new and larger mets), Liver (new and larger mets), Periportal lymph nodes (new mets)	Lungs (new mets), Liver (new and larger mets), Mediastinal, retroperitoneal and periaortic/perispinal lymph nodes (new and larger mets)	Lungs (new and larger mets), Bilateral pleural effusion, Bone (new mets)	—	—	—	—	—	—	—	—	—	—	—	Immunotherapy	NIVO (2 cycles) Nivolumab	NR	Chemotherapy	IrMdG (6 cycles) Irinotecan, Calcium folinate, Fluorouracil	SD	Chemotherapy	OxMdG (2 cycles) Oxaliplatin, Calcium folinate, Fluorouracil	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Hypertension, Ulcerative colitis, high cholestrol	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.07	—	1.07	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.67	6.73	13.47	15.5	—	—	—	—	—	—	—	—	—	—	—	3.83	4.3	7.83	11	13.73	14.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.67	15.77	15.5	—	15.77	3.67	1	1	1	1	R	LH20-31289	NR	abnormal	negative	negative	positive	positive	—	—
L	c.35G>A (p.Gly12Asp)	G12D	Normal	Positive	Positive	Positive	Positive	—	—	No	Treatment naïve	No	—	Subtotal colectomy	Sigmoid colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Mucinous adenocarcinoma	Specimen	Yes	4a	—	1c (peritoneum)	—	T4AN0M1C	M	AJCC 8	IVC	No	—	—	—	—	—	—	—	Chemotherapy	Irinotecan, Fluorouracil, Calcium Folinate (8 cycles)	Ovaries (new mets), Liver (new met), Peritoneum (Larger mets)	Ovaries (larger mets), Peritoneum (larger mets)	Ovaries (larger mets), peritoneum (new and larger mets), liver (new and larger mets), spleen (new met), lungs (new met)	—	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	Irinotecan, Fluorouracil, Calcium Folinate (5 cycles)	PD	Chemotherapy	Oxaliplatin, capecitabine (6 cycles)	PD	Chemotherapy	Trifluridine, tipiracil (1 cycle)	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.07	5.37	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.8	10.43	14.23	—	—	—	—	—	—	—	—	—	—	—	—	8.5	10.37	11.77	14.33	14.7	14.93	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7.8	19.83	17.27	—	19.83	7.8	1	1	1	1	L	—	B7	Normal	Positive	Positive	Positive	Positive	—	—
L	c.35G>A, p.(Gly12Asp)	G12D	Normal	Positive	Positive	Positive	Positive	—	—	No	Immunotherapy naïve	No	—	Hartmann's procedure	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	No	3	1B	NR	1A (Bone - sacrum)	T3N1BM1A	M	AJCC 8	IVA	Yes	3	Chemotherapy	Capecitabine	PR	Radiotherapy	45Gy in 25# (Rectum)	PR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Hypertension	Patient referred to oncologists for chemotherapy and follow up at local hospital - no further details available	2.1	3.27	2.1	3.27	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	8.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	30.87	13.5	—	30.87	30.87	—	1	1	1	L	NR	NR	Normal	Positive	Positive	Positive	Positive	—	—
L	Detected (c.35G>A)/p.(Gly12Asp)	G12D	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Ultra low Hartmanns procedure	Rectum	—	D14	Rectosigmoid tumour deposit	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	4A	1A	1C (peritoneum)	1C (Liver & Peritoneal)	T4AN1AM1C	W/M	AJCC 8	IVC	No	—	—	—	—	—	—	—	Chemotherapy	Irinotecan (8 cycles)	Liver (New and larger mets), Rectum (Residual)	Liver (Larger met)	Liver, Pelvic Lymph node (New mets), Lung (New mets, right upper and lower lobe)	Lung (New and larger mets, right upper and right lower lobe), Liver (New and larger mets), Pelvic nodes (Larger mets)	Lung (New mets, right lower lobe, left lower lobe), Bone (New met)	Lung, liver (Larger mets)	Bone (New and larger mets)	—	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (4 cycles; 3 weeks)	PD	Radiotherapy	8Gy in 1# (T10 Spine)	MR	Chemotherapy	Irinotecan (3 cycles)	PD	Chemotherapy	Capecitabine (1 cycle; 3 weeks)	NR	Other	Zoledronate (4 cycles)	NR	Radiotherapy	8Gy in 1# (T2-T5 Spine)	NR	Radiotherapy	8Gy in 1# (Left Femur)	NR	—	—	—	—	—	—	Deceased	Yes	Pneumonia, Metastatic Rectosigmoid cancer	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.23	5.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.6	7.77	10.77	13.1	16.2	19.03	21.27	—	—	—	—	—	—	—	—	13.6	15.7	19.67	19.67	20	20.7	21.6	22.3	22.67	24.77	22.93	22.93	23.67	23.67	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.6	26.67	25.03	—	26.67	2.6	1	1	1	1	L	—	D10	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	Detected (c.34G>A)/p.(Gly12Ser)	G12S	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	—	Laparoscopic assisted ultra low Hartmanns resection + reversal of ileostomy	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	No	3	—	X	—	T3N0M0	M	AJCC 8	IIA	Yes	3	Radiotherapy	45Gy 25# (Rectum)	SD	Chemotherapy	Capecitabine (1 cycle; 5 weeks)	SD	Chemotherapy	Oxaliplatine, Capecitabine (4 cycles)	Pelvis (local recurrence in rectal stump involving bladder, prostate, small intestine, anus) - resected	Pelvis (small intestine- local progression)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Anxiety and Depression	—	1.93	3.07	1.93	3.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	5.23	—	—	—	—	—	—	—	8.5	10.6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	12.57	21.33	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	12.57	22.4	21.33	—	22.4	12.57	1	1	1	1	L	—	A12	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
L	Detected (c.34G>A)/p.(Gly12Ser)	G12S	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Anterior resection of rectum and anastomosis of colon to rectum	Sigmoid colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Mucinous Adenocarcinoma	Specimen	Yes	3	1B	NR	—	T3N1BM0	M	AJCC 8	IIIA	No	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, Capecitabine (4 cycles)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.13	4.27	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	71.9	71.9	71.9	71.9	—	—	—	—	L	—	A5	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
R	Detected (c.34G>T), p.(Gly12Ser)	G12S	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Right hemicolectomy and anastomosis nec	Caecum	—	A2	Lung, right lower lobe	Immunotherapy naïve	B2	Lung, right lower lobe	Q3 - 2019	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	No	3	2A	NR	1A (Lung)	T3N2AM1A	M	AJCC 8	IVA	No	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, capecitabine (4 cycles)	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	Data Not Collected	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	1.4	—	13.1	13.1	—	—	—	—	3.3	6.13	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	—	82.37	85	85	82.37	—	—	—	—	R	—	A6	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	c.35G>T (p.Gly12Val)	G12V	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	Q1 - 2019	Extended right hemicolectomy	Descending colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Mucinous adenocarcinoma	Specimen	Yes	4a	1c	x	1a (liver)	T4AN1CM1A	W/M	AJCC 8	IVA	No	—	—	—	—	—	—	—	—	—	Liver (new and larger mets), Lung (new mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.5	8.57	1.5	—	8.57	1.5	1	1	1	1	L	—	NR	normal	positive	positive	positive	positive	—	—
R	c.35G>T (p.Gly12Val)	G12V	normal	positive	positive	positive	positive	—	—	No	Immunotherapy naïve	No	Q1 - 2019	Right hemicolectomy	Caecum	—	A14	Lymph node	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma (NOS)	Specimen	No	3	2b	x	1a (liver)	T3N2BM1A	W/M	AJCC 8	IVA	Yes	NR	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	SD	—	—	—	—	—	Liver (new and larger mets)	Liver (larger mets), Lung (new met)	—	—	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	IrinoCap (2 cycles) Irinotecan, Capecitabine	NR	Chemotherapy	IrMdG (2 cycles)	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Type 2 diabetes, hypertension, rheumatism	—	1.83	4.63	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	6.27	—	6.27	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	10.5	13.3	—	—	—	—	—	—	—	—	—	—	—	—	—	11.63	12.33	12.8	13.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	10.5	21.9	13.3	—	21.9	10.5	1	1	1	1	R	—	NR	normal	positive	positive	positive	positive	—	—
L	c.35G>T, p.(Gly12Val)	G12V	Normal	Positive	Positive	Positive	Positive	—	—	No	Treatment naïve	No	Q2 - 2021	Bilateral salpingoophorectomy	Sigmoid colon	—	D3	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	4A	1B	1C (right ovary, peritoneum, bladder)	1 (right Krukenberg)	T4AN1BM1C	W/M	AJCC 8	IVC	No	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, Capecitabine (2 cycles)	Liver (New mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	Oxaliplatin, Fluorouracil (6 cycles)	PR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.9	—	0.9	—	—	—	—	—	2.3	3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.73	—	—	—	—	—	—	—	—	—	—	—	—	—	—	4.5	7.07	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.73	—	42.37	49.27	49.27	3.73	1	—	—	1	L	LH21-9779	Bx	Normal	Positive	Positive	Positive	Positive	—	—
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	Detected c.37G>T p.(Gly13Cys)	G13C	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	—	Yes	—	Right VATS Proceed to posterolateral thoracotomy, middle lobectomy and wedge resection	—	Rectum	A1	Lung, right middle and lower lobe	Immunotherapy naïve	B2	Lung, right middle and lower lobe	Q2 - 2019	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Metastatic colorectal cancer	Primary tumour	Yes	3	2	NR	—	T3N2M0	NR	AJCC 5	III	Yes	NR	Chemotherapy	Capecitabine	PR	Radiotherapy	45Gy in 25# (rectum)	PR	Chemotherapy	Oxaliplatin, fluorouracil, folinate (9 cycles)	Lung (new mets)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Chemotherapy	Capecitabine (4 cycles)	SD	Radiotherapy	15Gy in 5# (pelvic side wall)	NR	Chemotherapy	Capecitabine (3 cycles)	PD	Chemotherapy	Capecitabine, oxaliplatin	SD	Other	Denosumab	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	Subsequent treatments and follow-up at local hospital (no details available)	0.03	2.17	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	5	34.6	34.6	—	—	—	—	6.3	11.47	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	29.87	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	59.07	62.1	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	29.87	79.7	38.77	—	79.7	29.87	1	1	1	1	L	BH16-20056	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
R	Detected. c.37G>T p.(Gly13Cys)	G13C	Abnormal	Negative	Negative	Positive	Positive	Not detected	Detected. c.1799T>A p.(Val600Glu)	No	Treatment naïve	No	Q1-2022	Right hemicolectomy and side to side anastomosis of ileum to transverse colon	Ascending Colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	3	—	NR	—	T3N0M0	P	AJCC 8	IIA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	R	LH22-10403	A7	Abnormal	Negative	Negative	Positive	Positive	Not detected	Detected. c.1799T>A p.(Val600Glu)
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	c.38G>A (p.Gly13Asp)	G13D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Laparoscopic high anterior resection	Sigmoid colon	—	A10	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	Yes	4a	1a	NR	1a (liver)	T4AN1AM1A	M/W	AJCC 8	IVA	No	—	—	—	—	—	—	—	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	Lung (new mets)	Lung (larger mets)	Lung (larger mets)	Lung (larger mets)	Lung (larger mets)	Bone (new mets), liver (new mets), lung (larger mets)	—	—	—	—	—	—	—	—	—	Radiotherapy	8 Gy in 1 # (Pelvic bone)	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	—	Hypertension	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.3	—	1.3	—	—	—	—	—	6.27	8.83	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.6	25.07	28.6	34.07	37.27	42.13	—	—	—	—	—	—	—	—	—	44	44	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.6	46.87	42.9	—	46.87	21.6	1	1	1	1	L	—	A3	normal	positive	positive	positive	positive	—	—
L	c.38G>A (p.Gly13Asp)	G13D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Robotic sigmoid colectomy	Sigmoid colon	—	A10	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	LH19-10316	A1	Resection margins	Q1 - 2019	Treatment naïve	F	Adenocarcinoma (NOS)	Specimen	Yes	3	1b	NR	—	T3N1BM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	—	—	Liver (new mets), Lungs (new mets)	Liver (larger mets), Lungs (new and larger mets)	Lungs (new and larger mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Atrial Fibrillation, Hypertension, Prior stroke / Transient Ischaemic Attack	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.07	—	2.07	—	—	—	—	2.07	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	18.63	24.43	33.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	18.63	38.43	33.5	—	38.43	18.63	1	1	1	1	L	LH19-529	NR	normal	positive	positive	positive	positive	—	—
R	c.38G>A (p.Gly13Asp)	G13D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Right hemicolectomy	Ascending colon	—	B15	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	No	4b	2a	NR	1a (liver)	T4BN2AM1A	M	AJCC 8	IVA	No	—	—	—	—	—	—	—	—	—	Liver (new and larger mets), Abdomen residual (larger tumour)	Liver (larger mets)	Liver (larger mets), Abdomen residual (larger tumour)	Liver (larger mets), Abdomen residual (larger tumour)	Lung (new mets), Liver (larger mets), Abdomen residual (larger tumour)	—	—	—	—	—	—	—	—	—	—	Chemotherapy	IrMdG (8 cycles) Irinotecan, Calcium folinate, Fluorouracil	MR	Chemotherapy	OxaliCap (2 cycles) Oxaliplatin, Capecitabine	NR	Chemotherapy	Capecitabine (2 cycles)	SD	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	1a) Metastatic ascending colon adenocarcinoma	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.57	6.47	10.37	16.27	18.4	—	—	—	—	—	—	—	—	—	—	4.43	7.7	11.13	12.33	12.57	13.97	17.73	20.53	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.57	23	19.77	—	23	3.57	1	1	1	1	R	—	B11	normal	positive	positive	positive	positive	—	—
L	c.38G>A (p.Gly13Asp)	G13D	abnormal	negative	negative	positive	positive	—	—	No	Treatment naïve	No	—	Total colectomy	Rectum	—	A12	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	Yes	4a	1a	x	—	T4aN1AM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	Chronic schizophrenia	Subsequent new primary colorectal adenocarcinoma in rectal stump (pT3 pN0, KRAS G13D mutation, pMMR)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	78.23	78.23	78.23	78.23	—	—	—	—	L	—	A9	abnormal	negative	negative	positive	positive	—	—
R	c.38G>A (p.Gly13Asp)	G13D	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	—	Robotic Right Hemicolectomy	Ascending colon	—	A34	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Mucinous adenocarcinoma	Specimen	No	3	2a	NR	—	T3N2AM0	—	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	Liver (new mets)	Portocaval lymph node (new met)	Lungs (new mets), Liver (larger mets), Lymph nodes (new mets), Omentum (new mets)	Lung, pleura (new and larger mets), Liver (new and larger mets), Peritoneum (larger mets), Lymph nodes (larger mets), Bone (new mets)	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	IrinoCap (3 cycles) Irinotecan, Capecitabine	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Obesity	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.3	—	1.3	—	—	—	—	—	3.23	6.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	14.33	15.07	23.9	26.53	—	—	—	—	—	—	—	—	—	—	—	24.9	26.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	14.33	27.63	27.43	—	27.63	14.33	1	1	1	1	R	—	NR	normal	positive	positive	positive	positive	—	—
R	c.38G>A (p.Gly13Asp)	G13D	abnormal	negative	negative	positive	positive	—	—	No	Treatment naïve	No	—	Laparoscopic right hemicolectomy	Caecum	—	A13	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Mucinous adenocarcinoma	Specimen	Yes	3	1a	x	—	T3N1AM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Other	Aspirin (300 mg/day) (plus lansoprazole)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.67	—	1.67	—	—	—	—	—	3.07	73.57	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	66.8	73.57	73.57	66.8	—	—	—	—	R	—	A9	abnormal	negative	negative	positive	positive	—	—
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	Detected (c.351A>C / p.(Lys117Asn))	K117N	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Anterior resection of rectum and anastomosis of colon to rectum	Rectum	—	C20	mesorectum	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	3	1C	NR	—	T3N1CM0	M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (1 cycle)	Liver (New mets)	Lung (New met)	Lung (Larger met)	Rectum (recurrence)	Lung (New met)	Chest wall/pleura (New mets)	Lung, Pleura (New and larger mets)	Pleura/rib (larger met)	Lung (larger met), pleura/rib (larger met)	Hemithorax (Larger mets)	Brain (New met)	—	—	—	—	Radiotherapy	25Gy in 5# (Rectum)	PR	Chemotherapy	Raltitrexed, Oxaliplatin (2 cycles)	PR	Radiotherapy	16Gy2# (Left Rib)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	NR	Adjuvant therapy stopped because patient had MI	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.63	—	1.63	—	—	—	—	—	3.9	4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	17.23	19.73	22.97	23.13	33.97	34.93	37.27	41.63	46.87	48.8	66.87	—	—	—	—	26.23	26.37	39.2	39.9	47.97	48.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	17.23	69.83	69.03	—	69.83	17.23	1	1	1	1	L	LH19-13227	A1	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
R	Detected (c.351A>T) / p.(Lys117Asn)	K117N	Abnormal	Negative	Negative	Positive	Negative	Not detected	Not detected	No	Treatment naïve	No	—	Colectomy and anastomosis nec	Caecum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	3	—	NR	—	T3N0M0	M	AJCC	IIA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	R	—	A7	Abnormal	Negative	Negative	Positive	Negative	Not detected	Not detected
L	Detected (c.351A>C,p.(Lys117Asn).	K117N	Normal	Positive	Positive	Positive	Positive	NR	NR	No	Immunotherapy naïve	Yes	—	Perineal resection of rectum HFQ	Rectum	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Primary tumour	Yes	3	1C	NR	—	T3N1CM0	M	AJCC 8	IIIB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	LH19-13227	A1	Normal	Positive	Positive	Positive	Positive	NR	NR
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
R	c.183A>C (p.Gln61His)	Q61H	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	Q3 - 2020	Lap converted to open right hemicolectomy	Caecum	—	A15	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Mucinous adenocarcinoma	Specimen	No	4a	2b	x	—	T4AN2BM0	P	AJCC 8	IIIC	No	—	—	—	—	—	—	—	Chemotherapy	OxaliCap (4 cycles) Oxaliplatin, Capecitabine	Surgical site (recurrence), retroperitoneum, peritoneum (new mets), Aortocaval lymph node (new met)	Small interval increase in retroperitoneal, peritoneal and nodal disease	Retroperitoneum, peritoneum (new and larger mets), nodes (larger mets), Lung (new met)	Peritoneum, retroperitoneum (disease progression), Lung (larger met, pleural effusion)	—	—	—	—	—	—	—	—	—	—	—	Chemotherapy	IrinoCap (18 cycles) Irinotecan, Capecitabine	PD	Chemotherapy	OxaliCap (3 cycles) Oxaliplatin, Capecitabine	PD	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.17	—	1.17	—	—	—	—	—	3.23	6.83	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11.47	15.2	22.33	25.83	—	—	—	—	—	—	—	—	—	—	—	12.43	22.73	23.23	25.27	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11.47	26.67	25.83	—	26.67	11.47	1	1	1	1	R	LH20-19171	NR	normal	positive	positive	positive	positive	—	—
R	c.183A>C (p.Gln61His)	Q61H	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	Q3 - 2020	Right hemicolectomy	Caecum	—	A13	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Mucinous signet ring cell adenocarcinoma	Specimen	No	4b	2b	x	1c (peritoneum, liver, ileocolic nodes)	T4BN2BM1C	P	AJCC 8	IVC	No	—	—	—	—	—	—	—	Chemotherapy	IrMdG (2 cycles) Irinotecan, Calcium folinate, Fluorouracil	Peritoneum, omentum (larger mets), ascites, Liver (new and larger mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Angina	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.6	2.07	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.03	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.03	2.83	2.03	—	2.83	2.03	1	1	1	1	R	—	NR	normal	positive	positive	positive	positive	—	—
L	Detected (c.183A>T) / p.(Gln61His)	Q61H	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected	No	Immunotherapy naïve	No	Q3-2021	Abdominoperineal excision of rectum and end colostomy	Rectum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	No	4A	—	X	1A (Lung)	T4AN0M1A (Lung)	W/M	AJCC	IVA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	L	LH20-13186	NR	Normal	Positive	Positive	Positive	Positive	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
R	c.181C>A (p.Gln61Lys)	Q61K	—	—	—	—	—	—	—	No	Treatment naïve	No	—	Right hemicolectomy	Right (ascending) colon	—	A10	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	4b	2b	x	—	T4BN2BM0	W/M	AJCC 7	IIIC	No	—	—	—	—	—	—	—	Chemotherapy	OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL (6 cycles)	Lung (new mets), Liver (new met)	Lung (Larger met), Liver (Larger and new mets)	Peritoneum (New mets)	Liver (larger met), Peritoneum (larger mets), Lungs (larger mets)	Lung (Larger mets), Liver (Larger mets), Peritoneum (larger mets), Retroperitoneal ymph nodes (new mets) Bone (new met)	Liver (Larger mets), Peritoneum (Larger mets), Bone (New mets)	—	—	—	—	—	—	—	—	—	Chemotherapy	IRINOTECAN, CALCIUM FOLINATE, FLUOROURACIL (8 cycles)	SD	Chemotherapy	IRINOTECAN, CALCIUM FOLINATE, FLUOROURACIL (6 cycles)	PD	Radiotherapy	8Gy in 1# (lumbar spine)	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	1a) Metastatic colon cancer 2. Type II diabetes mellitus, hypothyroidism	Type 2 diabetes millitus, hypothyroidism	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	1.17	—	1.17	—	—	—	—	—	2.67	5.57	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	16.9	19.7	24.47	26.2	29.03	31.7	—	—	—	—	—	—	—	—	—	21	24.3	29.63	32	33.47	33.47	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	16.9	33.83	33.83	—	33.83	16.9	1	1	1	1	R	—	—	—	—	—	—	—	—	—
R	Detected (c.181C>A) /p.(Gln61Lys)	Q61K	Abnormal	Negative	Negative	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Right hemicolectomy and anastomosis nec	Caecum	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	3	—	X	—	T3N0M0	W/M	AJCC 8	IIA	No	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Alive	—	—	NR	Subsequent new primary adenocarcinoma of rectum (pT2 pN2A pR0, pM1 pRx (metastatic deposit beween rectum and vagina), pMMR); anterior resection and adjuvant capecitabine	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	2.57	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	24.6	69.7	69.7	24.6	—	—	—	—	R	LH20-9530	NR	Abnormal	Negative	Negative	Positive	Positive	Not detected	Not detected
R	Detected c.181C>A / p.(Gln61Lys)	Q61K	Abnormal	Negative	Negative	Positive	Positive	Not detected	Not detected	No	Treatment naïve	No	—	Right hemicolectomy and side to side anastomosis of ileum to transverse colon	Right (ascending) colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Specimen	Yes	3	—	NR	—	T3N0M0	P	AJCC	IIA	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	R	LH20-37742	A1	Abnormal	Negative	Negative	Positive	Positive	Not detected	Not detected
R	Detected (c.181C>A), p.(Gln61Lys)	Q61K	Normal	Positive	Positive	Positive	Positive	Not Detected	Not Detected	No	Treatment naïve	No	—	Right hemicolectomy and anastomosis nec	Ascending colon	—	B2	Duodenal nodule/wedge	Immunotherapy naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	F	Adenocarcinoma	Primary tumour	Yes	3	1	X	—	T3N1M0	M/P	AJCC 5	III	No	—	—	—	—	—	—	—	Chemotherapy	Capecitabine (4 cycles)	Pelvis (recurrence)	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Chemotherapy	Irinotecan, fluorouracil, folinate (12 cycles)	SD	Chemotherapy	Oxaliplatin, fluorouracil, folinate (5 cycles)	PR	Radiotherapy	30Gy in 10# (right pelvic wall)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	Data Not Collected	—	—	—	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	—	—	34	—	—	—	—	—	3.83	6.87	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	36.3	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	38.07	43.67	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	Data Not Collected	36.3	53.23	52.37	—	53.23	36.3	1	1	1	1	R	—	NR	Normal	Positive	Positive	Positive	Positive	Not Detected	Not Detected
R	Detected. c.181C>A, p.(Gln61Lys)	Q61K	Abnormal	Negative	Negative	Clonal loss	Clonal loss	Not detected	Not detected	No	Treatment naïve	No	—	Colectomy and anastomosis nec	Ascending Colon	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma	Specimen	Yes	4A	—	x	—	T4AN0M0	M/P	AJCC 8	IIB	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	R	LH22-06214	A5	Abnormal	Negative	Negative	Clonal loss	Clonal loss	Not detected	Not detected
Side_L_R	KRAS_Mutation	KRAS_Group	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation	Any Immunotherapy	Specimen Treatment Subgrouping	Specimen Is A Recurrence	Specimen Surgery Date	Specimen Surgery	Specimen Tumour Site	Primary Tumour Site	Matched Met 1 Block Number	Matched Met 1 Site	Matched Met 1 Treatment Subgrouping	Matched Met 2 Block Number	Matched Met 2 Site	Matched Met 2 Surgery Date	Matched Met 2 Treatment Subgrouping	Anonymized ID Matched Met 3	Matched Met 3 Block Number	Matched Met 3 Site	Matched Met 3 Surgery Date	Matched Met 3 Treatment Subgrouping	Anonymized ID Matched Met 4	Matched Met 4 Block Number	Matched Met 4 Site	Matched Met 4 Surgery Date	Matched Met 4 Treatment Subgrouping	Anonymized ID Matched Met 5	Matched Met 5 Block Number	Matched Met 5 Site	Matched Met 5 Surgery Date	Matched Met 5 Treatment Subgrouping	Anonymized ID Normal Tissue	Matched Normal Tissue Block Number	Matched Normal Tissue Site	Matched Normal Tissue Surgery Date	Matched Normal Treatment Subgrouping	Gender	Specimen Histological Diagnosis	Staging/grading Info Provided For:	Resection Margins Clear	pT	pN	pM	cM	TNM Stage	Grade	Staging Criteria	Stage At Dx	Any Neoadjuvant Therapy	Response To Neoadjuvant Therapy (TRS Score)	Neoadjuvant Tx1	Neoadjuvant Tx1 Agent	Tumour Response Neoadjuvant Tx1	Neoadjuvant Tx2	Neoadjuvant Tx2 Agent	Tumour Response Neoadjuvant Tx2	Adjuvant Tx1	Adjuvant Tx1 Agent	Sites Recurrence/ Progression 1	Sites Recurrence/ Progression 2	Sites Recurrence/ Progression 3	Sites Recurrence/ Progression 4	Sites Recurrence/ Progression 5	Sites Recurrence/ Progression 6	Sites Recurrence/ Progression 7	Sites Recurrence/ Progression 8	Sites Recurrence/ Progression 9	Sites Recurrence/ Progression 10	Sites Recurrence/ Progression 11	Sites Recurrence/ Progression 12	Sites Recurrence/ Progression 13	Sites Recurrence/ Progression 14	Sites Recurrence/ Progression 15	Subsequent Tx1	Subsequent Tx1 Agent	Tumour Response To Subsequent Tx1	Subsequent Tx2	Subsequent Tx2 Agent	Tumour Response To Subsequent Tx2	Subsequent Tx3	Subsequent Tx3 Agent	Tumour Response To Subsequent Tx3	Subsequent Tx4	Subsequent Tx4 Agent	Tumour Response To Subsequent Tx4	Subsequent Tx5	Subsequent Tx5 Agent	Tumour Response To Subsequent Tx5	Subsequent Tx6	Subsequent Tx6 Agent	Tumour Response To Subsequent Tx6	Subsequent Tx7	Subsequent Tx7 Agent	Tumour Response To Subsequent Tx7	Subsequent Tx8	Subsequent Tx8 Agent	Tumour Response To Subsequent Tx8	Subsequent Tx9	Subsequent Tx9 Agent	Tumour Response To Subsequent Tx9	Current Status	Death Tumour Related	Cause Of Death	Concurrent Medical Conditions	Comments From Clinical Team	TTE Neoadjuvant Tx1 Start Date	TTE Neoadjuvant Tx1 End Date	TTE Neoadjuvant Tx2 Start Date	TTE Neoadjuvant Tx2 End Date	TTE Neoadjuvant Tx3 Start Date	TTE Neoadjuvant Tx3 End Date	TTE Neoadjuvant Tx4 Start Date	TTE Neoadjuvant Tx4 End Date	TTE Neoadjuvant Tx5 Start Date	TTE Neoadjuvant Tx5 End Date	TTE Neoadjuvant Tx6 Start Date	TTE Neoadjuvant Tx6 End Date	TTE Neoadjuvant Tx7 Start Date	TTE Neoadjuvant Tx7 End Date	TTE Neoadjuvant Tx8 Start Date	TTE Neoadjuvant Tx8 End Date	TTE Neoadjuvant Tx9 Start Date	TTE Neoadjuvant Tx9 End Date	TTE Neoadjuvant Tx10 Start Date	TTE Neoadjuvant Tx10 End Date	TTE Specimen Surgery Date	TTE Primary Surgery Date	TTE Matched Met 1 Surgery Date	TTE Matched Met 2 Surgery Date	TTE Matched Met 3 Surgery Date	TTE Matched Met 4 Surgery Date	TTE Matched Met 5 Surgery Date	TTE Matched Normal Tissue Surgery Date	TTE Adjuvant Tx1 Start Date	TTE Adjuvant Tx1 End Date	TTE Adjuvant Tx2 Start Date	TTE Adjuvant Tx2 End Date	TTE Adjuvant Tx3 Start Date	TTE Adjuvant Tx3 End Date	TTE Adjuvant Tx4 Start Date	TTE Adjuvant Tx4 End Date	TTE Adjuvant Tx5 Start Date	TTE Adjuvant Tx5 End Date	TTE Adjuvant Tx6 Start Date	TTE Adjuvant Tx6 End Date	TTE Adjuvant Tx7 Start Date	TTE Adjuvant Tx7 End Date	TTE Adjuvant Tx8 Start Date	TTE Adjuvant Tx8 End Date	TTE Adjuvant Tx9 Start Date	TTE Adjuvant Tx9 End Date	TTE Adjuvant Tx10 Start Date	TTE Adjuvant Tx10 End Date	TTE Adjuvant Tx11 Start Date	TTE Adjuvant Tx11 End Date	TTE Adjuvant Tx12 Start Date	TTE Adjuvant Tx12 End Date	TTE Adjuvant Tx13 Start Date	TTE Adjuvant Tx13 End Date	TTE Adjuvant Tx14 Start Date	TTE Adjuvant Tx14 End Date	TTE Adjuvant Tx15 Start Date	TTE Adjuvant Tx15 End Date	TTE Date Recurrence/ Progression 1	TTE Date Recurrence/ Progression 2	TTE Date Recurrence/ Progression 3	TTE Date Recurrence/ Progression 4	TTE Date Recurrence/ Progression 5	TTE Date Recurrence/ Progression 6	TTE Date Recurrence/ Progression 7	TTE Date Recurrence/ Progression 8	TTE Date Recurrence/ Progression 9	TTE Date Recurrence/ Progression 10	TTE Date Recurrence/ Progression 11	TTE Date Recurrence/ Progression 12	TTE Date Recurrence/ Progression 13	TTE Date Recurrence/ Progression 14	TTE Date Recurrence/ Progression 15	TTE Subsequent Tx1 Start Date	TTE Subsequent Tx1 End Date	TTE Subsequent Tx2 Start Date	TTE Subsequent Tx2 End Date	TTE Subsequent Tx3 Start Date	TTE Subsequent Tx3 End Date	TTE Subsequent Tx4 Start Date	TTE Subsequent Tx4 End Date	TTE Subsequent Tx5 Start Date	TTE Subsequent Tx5 End Date	TTE Subsequent Tx6 Start Date	TTE Subsequent Tx6 End Date	TTE Subsequent Tx7 Start Date	TTE Subsequent Tx7 End Date	TTE Subsequent Tx8 Start Date	TTE Subsequent Tx8 End Date	TTE Subsequent Tx9 Start Date	TTE Subsequent Tx9 End Date	TTE Subsequent Tx10 Start Date	TTE Subsequent Tx10 End Date	TTE Subsequent Tx11 Start Date	TTE Subsequent Tx11 End Date	TTE Subsequent Tx12 Start Date	TTE Subsequent Tx12 End Date	TTE Subsequent Tx13 Start Date	TTE Subsequent Tx13 End Date	TTE Subsequent Tx14 Start Date	TTE Subsequent Tx14 End Date	TTE Subsequent Tx15 Start Date	TTE Subsequent Tx15 End Date	TTE Recurrence (PFS)	TTE Death (OS And PFS)	TTE Date Last Follow-Up (PFS)	TTE Date Last Seen (OS)	TTE Overall Survival (OS) In Months	TTE Progression Free Survival (PFS) In Months	Event (Recurrence/Progression)	Event (Cancer Death)	Event (Death; All Causes)	Event (Recurrence Or Cancer Death	Side_L_R	SpecNumber_Used_For_MolecularTesting_IfDifferent	Block_Used_For_LynchScreening_MMR_IHC	MMR_Result_Normal_Abnormal	MLH1_IHC_Pos_Neg_ClonalNeg	PMS2_IHC_Pos_Neg_ClonalNeg	MSH2_IHC_Pos_Neg_ClonalNeg	MSH6_IHC_Pos_Neg_ClonalNeg	NRAS_Mutation	BRAF_Mutation
L	c.182A>T (p.Gln61Leu)	Q61L	normal	positive	positive	positive	positive	—	—	No	Treatment naïve	No	Q2 - 2020	Abdominoperineal excision of rectum	Rectum	—	A13	Lymph node	Treatment naïve	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	M	Adenocarcinoma (NOS)	Specimen	No	3	1a	x	—	T3N1AM0	W/M	AJCC 8	IIIB	No	—	—	—	—	—	—	—	—	—	Lung (new met)	Liver (new mets)	Liver (new mets)	Pelvis (local recurrence), Peritoneum (new met)	Local recurrence (progression) Liver (larger mets), Peritoneum (larger met).Lungs (new and larger mets)	Local recurrence (progression) Liver (new and larger mets)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	Deceased	Yes	NR	NR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.3	—	3.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.83	23.07	24.03	24.13	27.63	35.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	21.83	36.17	35.7	—	36.17	21.83	1	1	1	1	L	LH20-4153	NR	normal	positive	positive	positive	positive	—	—